AstraZeneca PLC (AZN)vsInspire Medical Systems Inc (INSP)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
INSP
Inspire Medical Systems Inc
$53.41
-3.08%
HEALTHCARE · Cap: $1.54B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6341% more annual revenue ($58.74B vs $911.98M). AZN leads profitability with a 17.4% profit margin vs 16.0%. INSP trades at a lower P/E of 10.9x. INSP earns a higher WallStSmart Score of 66/100 (B-).
AZN
Buy64
out of 100
Grade: C+
INSP
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+86.9%
Fair Value
$519.34
Current Price
$53.41
$465.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Earnings expanding 308.4% YoY
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : INSP
The strongest argument for INSP centers on P/E Ratio, EPS Growth, Altman Z-Score. Profitability is solid with margins at 16.0% and operating margin at 17.1%. Revenue growth of 12.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : INSP
The primary concerns for INSP are Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a value stock while INSP is a mature play — different risk/reward profiles.
INSP carries more volatility with a beta of 0.86 — expect wider price swings.
INSP is growing revenue faster at 12.2% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
INSP scores higher overall (66/100 vs 64/100), backed by strong 16.0% margins and 12.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Inspire Medical Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?